By SmokerBar Editorial Team

If you have ever wondered whether VELO nicotine pouches are classified as a “drug” — you are not alone. The question touches on law, public health, and how we think about nicotine itself.

The short answer is nuanced. As the reference article explains: “Nicotine pouches aren’t strictly classified as a drug. Like cigarettes, they contain nicotine, which is an addictive substance. However, they contain 99% fewer harmful substances than conventional cigarettes.”

In this 2026 guide, we will break down the legal classification of VELO, explain the science behind nicotine’s regulatory status, and provide a balanced perspective on what this means for adult users.

The Short Answer: No — But the Distinction Matters Legally

VELO nicotine pouches are not classified as drugs in the same way that pharmaceuticals are. Instead, they are regulated as tobacco products under federal law.

According to the 2009 Family Smoking Prevention and Tobacco Control Act, any product made or derived from tobacco that contains nicotine is considered a tobacco product — even if it contains no tobacco leaf and even if the nicotine is synthetically derived. Because VELO contains nicotine (whether derived from tobacco plants or manufactured synthetically in VELO Plus), it falls squarely under this regulatory framework.

As the Rhode Island Department of Health explains: “Some nicotine pouches call themselves ‘tobacco-free’ because their nicotine was made in a lab. They are still considered tobacco products, which can be both harmful and addictive”.

Why the Confusion?

The confusion arises because nicotine itself — as a chemical compound — can be and has been classified as a drug. In fact, in 1996, the FDA asserted jurisdiction to regulate tobacco products, concluding that nicotine is a “drug” and that cigarettes and smokeless tobacco are “devices” that deliver this drug to the body. The FDA determined that nicotine in cigarettes and smokeless tobacco “does affect the structure or any function of the body” — meeting the legal definition of a drug under the Federal Food, Drug, and Cosmetic Act.

However, there is a crucial distinction. When nicotine is delivered through tobacco products (including VELO), the products are regulated by the FDA’s Center for Tobacco Products (CTP). When nicotine is delivered through pharmaceutical products designed for smoking cessation (like nicotine gum, patches, or lozenges), they are regulated as drugs by the FDA’s Center for Drug Evaluation and Research (CDER).

The difference is not the nicotine itself — it is the intended use and regulatory pathway.

What Does “Tobacco Product” Mean for VELO?

Being classified as a tobacco product has several practical implications.

VELO pouches are subject to the same marketing restrictions, age verification requirements, and health warnings as cigarettes and other tobacco products. You must be at least 21 years old (in the US) or 18+ in other markets to purchase VELO. The packaging must carry nicotine warning statements. Advertising is restricted from targeting youth.

The FDA’s import alert list specifically categorises VELO as “98-A- tobacco products, intended for consumer use”. This classification applies regardless of whether the nicotine is derived from tobacco plants (standard VELO) or synthetically produced (VELO Plus).

Importantly, the FDA has not approved VELO or any nicotine pouch as a safe and effective smoking cessation aid. If you are looking to quit nicotine entirely, medically approved cessation products remain the gold standard.

VELO’s FDA Status in 2026

As of April 2026, VELO’s regulatory status in the United States is still evolving. The FDA launched a fast‑track review program for nicotine pouch products, but approvals have stalled as agency scientists weigh concerns about youth uptake and risks to non‑users against potential harm‑reduction benefits for smokers. Applications for newer versions of VELO remain pending, with specific concerns relating to “risks to youth or other non‑users, such as driving addiction in adults who do not already smoke”.

The FDA acknowledges that “nicotine products are highly addictive and are not risk‑free even for adults, while nicotine can harm developing brains. Pouches, however, are generally less harmful than cigarettes, and when smokers switch completely scientific data indicates they can lower health risks”.

Is Nicotine a Drug? The Scientific Perspective

From a purely chemical and pharmacological standpoint, nicotine is a psychoactive substance. It binds to nicotinic acetylcholine receptors in the brain, triggering the release of dopamine and other neurotransmitters. This produces the familiar sensations of alertness, focus, and satisfaction — and is the mechanism behind nicotine’s addictive potential.

The FDA has formally determined that nicotine in cigarettes and smokeless tobacco is a “drug” because it “affects the structure or any function of the body” within the meaning of the Federal Food, Drug, and Cosmetic Act. In the 1990s, the FDA asserted jurisdiction over tobacco products on precisely this basis: that nicotine is a drug and that cigarettes and smokeless tobacco are “devices” for delivering that drug.

However, the key distinction is that Congress later passed the Family Smoking Prevention and Tobacco Control Act of 2009, which created a separate regulatory pathway for tobacco products. This act established the FDA’s Center for Tobacco Products (CTP) and gave it authority over tobacco products — including those containing nicotine — as a distinct category separate from pharmaceutical drugs.

In practice, this means that nicotine delivered through tobacco products is regulated differently from nicotine delivered through medicinal products. The nicotine molecule itself is the same; the difference is in the regulatory framework, intended use, and marketing.

VELO’s Place on the Risk Continuum

While VELO is not classified as a drug, the scientific evidence clearly distinguishes it from cigarettes. A 2026 narrative review published in Internal and Emergency Medicine concluded that nicotine pouches “occupy the lowest end of the toxicant risk continuum,” with harmful constituents such as tobacco‑specific nitrosamines being largely undetectable or present at negligible levels compared to snus and combustible cigarettes. Smokers who switch to nicotine pouches experience “reductions in toxicant exposure comparable to complete smoking cessation”.

A February 2026 mini‑review in Frontiers in Oral Health found that “toxicological analyses reveal significantly lower levels of harmful constituents relative to cigarettes and traditional smokeless tobacco, and short‑term clinical studies report reductions in oral mucosal irritation and gingival inflammation among exclusive users”. However, the review also noted that “no long‑term epidemiological evidence is currently available to assess their potential impact upon oral carcinogenesis”.

In practical terms: switching completely from cigarettes to VELO dramatically reduces exposure to harmful chemicals — but VELO is not risk‑free, and long‑term effects are still being studied.

Side Effects and Health Considerations

Like all nicotine products, VELO can cause side effects — particularly for new users or those using higher strengths. Common side effects include nausea, dizziness, headache, and a burning sensation at the application site.

The 2025–2026 research also points to specific risks:

• Gum irritation and oral lesions: Multiple studies indicate that oral mucosal lesions are common among nicotine pouch users, with reported rates ranging from 70% to 96%. Approximately 18% to 57% of users may show signs of irreversible gingival recession.

• Addiction potential: While VELO has lower abuse liability than cigarettes — a 2025 clinical study found that product liking scores for Velo ONPs were “significantly lower than cigarettes (p < 0.0042) regardless of nicotine level, pouch size, or flavor, but similar to NRT gum” — nicotine dependence can still develop with regular use. The study concluded that “Velo ONPs demonstrated an AL profile lower than cigarettes and similar to NRT gum, suggesting a reduced potential for abuse compared to cigarettes”.

• Nicotine poisoning risk: Nicotine pouches can poison babies, toddlers, and pets who may accidentally eat them. According to US Poison Center data, children under 6 years old accounted for the majority of nicotine pouch exposure cases (73.1%).

What the 2026 Research Says About VELO and Public Health

The scientific community continues to evaluate nicotine pouches through the lens of tobacco harm reduction.

A 2026 narrative review concluded: “Nicotine pouches could represent a promising harm reduction tool with a risk profile likely adjacent to pharmaceutical nicotine replacement therapies, and could be considered by clinicians as substitutes for smoking in smokers unable or unwilling to quit with currently approved methods”.

The UK government has explicitly acknowledged that nicotine pouches carry lower health risks than smoking and confirm their role as a harm reduction tool, stating: “Nicotine pouches may carry lower health risks than smoking because they do not involve inhaling harmful substances from burning tobacco, such as tar and carbon monoxide”. However, the government also warns that nicotine pouches have high nicotine content, fast absorption, and are flavoured, which could lead to nicotine dependence, and that minors should not use them.

The FDA’s position, as articulated in April 2026, is that while nicotine products are “highly addictive and are not risk‑free even for adults,” pouches “are generally less harmful than cigarettes, and when smokers switch completely scientific data indicates they can lower health risks”.

Who Should Use VELO? (And Who Should Not)

Based on the 2026 evidence, here is clear guidance:

VELO may be appropriate for:

• Adult smokers (21+ in the US, 18+ in most other markets) who have tried to quit using other methods and would otherwise continue smoking

• Adults who understand that nicotine is addictive and carries cardiovascular and oral health risks

• Adults who will switch completely from cigarettes (not dual use)

VELO is NOT appropriate for:

• Anyone under the legal age (nicotine harms developing brains)

• Non‑nicotine users of any age — there is no benefit to starting

• Pregnant or breastfeeding women

• Individuals with heart disease, high blood pressure, or other cardiovascular conditions without consulting a doctor

• Anyone who would use VELO while continuing to smoke or vape (dual use provides minimal health benefit)

• Individuals who have had an allergic reaction to nicotine or any ingredient in VELO

The Bottom Line: Legal Classification vs. Health Reality

So, is VELO considered a drug?

From a strict legal standpoint: No. VELO nicotine pouches are classified and regulated as tobacco products under the Family Smoking Prevention and Tobacco Control Act. They are not approved as pharmaceutical drugs or smoking cessation aids.

From a scientific standpoint: Nicotine itself is a psychoactive substance that meets the pharmacological definition of a drug. It affects brain function, is addictive, and can have both positive (focus, alertness) and negative (cardiovascular strain, dependence) effects.

For the consumer: The most important distinction is not whether VELO is a “drug” — it is understanding that VELO is substantially less harmful than continued cigarette smoking, but not risk‑free. As the reference article notes, VELO contains “99% fewer harmful substances than conventional cigarettes”. However, it still contains nicotine, which is addictive.

If you are an adult smoker who has tried to quit but continues to smoke, switching completely to VELO represents a meaningful harm reduction step. But if you do not already use nicotine, there is no benefit to starting. And for those who want to quit nicotine entirely, the healthiest choice is to stop all nicotine use.

Shop Authentic VELO Nicotine Pouches at SmokerBar

At SmokerBar, we carry the full range of authentic VELO nicotine pouches — from 4 mg to 17 mg — in all your favourite flavours: Freezing Peppermint, Ruby Berry, Purple Grape, Bright Spearmint, Tropical Mango, and more. All products are sourced directly from authorised distributors, stored fresh, and shipped discreetly with age verification (21+ in the US, 18+ in other markets).

Browse our VELO collection today — and make an informed choice.

Disclaimer: This product contains nicotine. Nicotine is an addictive chemical. For adult nicotine users aged 21+ (US) or 18+ (other markets). This article is for informational purposes and does not constitute legal or medical advice. VELO is not a smoking cessation aid and has not been approved by the FDA for quitting smoking. If you do not use nicotine, do not start. Keep out of reach of children and pets. If you smoke cigarettes, quitting altogether is the healthiest choice. Switching to VELO is a less harmful alternative for adult smokers who would otherwise continue smoking.